CNS Drugs

, Volume 23, Issue 10, pp 817–835 | Cite as

Potential Influences of Complementary Therapy on Motor and Non-Motor Complications in Parkinson’s Disease

Review Article

Abstract

Nearly two-thirds of patients with Parkinson’s disease (PD) use vitamins or nutritional supplements, and many more may use other complementary therapies, yet <50% of patients have discussed the use of these complementary therapies with a healthcare professional. Physicians should be aware of the complementary therapies their patients with PD are using, and the possible effects of these therapies on motor and non-motor symptoms.

Complementary therapies, such as altered diet, dietary supplements, vitamin therapy, herbal supplements, caffeine, nicotine, exercise, physical therapy, massage therapy, melatonin, bright-light therapy and acupuncture, may all influence the symptoms of PD and/or the effectiveness of dopaminergic therapy. Preliminary evidence suggests complementary therapy also may influence non-motor symptoms of PD, such as respiratory disorders, gastrointestinal disorders, mood disorders, sleep and orthostatic hypotension. Whenever possible, clinicians should ensure that complementary therapy is used appropriately in PD patients without reducing the benefits of dopaminergic therapy.

Supplementary material

40263_2012_23100817_MOESM1_ESM.pdf (103 kb)
Supplementary material, approximately 105 KB.

References

  1. 1.
    Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology 2007 Jan 30; 68(5): 326–37PubMedCrossRefGoogle Scholar
  2. 2.
    Bhidayasiri R, Truong DD. Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 2008 Mar 15; 266(1–2): 204–15PubMedCrossRefGoogle Scholar
  3. 3.
    Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 2008 Mar 15; 266(1–2): 216–28PubMedCrossRefGoogle Scholar
  4. 4.
    Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 2006 Feb; 45(2): 109–36PubMedCrossRefGoogle Scholar
  5. 5.
    Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41(4): 261–309PubMedCrossRefGoogle Scholar
  6. 6.
    Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000 Oct 18; 284(15): 1931–8CrossRefGoogle Scholar
  7. 7.
    Rascol O, Brooks DJ, Korczyn AD, et al., on behalf of the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000 May 18; 342(20): 1484–91PubMedCrossRefGoogle Scholar
  8. 8.
    Wolfrath SC, Borenstein AR, Schwartz S, et al. Use of nutritional supplements in Parkinson’s disease patients. Mov Disord 2006 Aug; 21(8): 1098–101PubMedCrossRefGoogle Scholar
  9. 9.
    Sawabini KA, Evatt ML. Alternative therapy use in patients with cervical dystonia [abstract no. P226]. Mov Disord 2004; 19Suppl. 9: S90Google Scholar
  10. 10.
    Remple MS, Sarpong Y, Neimat JS. Frontiers in the surgical treatment of Parkinson’s disease. Expert Rev Neurother 2008 Jun; 8(6): 897–906PubMedCrossRefGoogle Scholar
  11. 11.
    Uc EY, Follett KA. Deep brain stimulation in movement disorders. Semin Neurol 2007 Apr; 27(2): 170–82PubMedCrossRefGoogle Scholar
  12. 12.
    Suchowersky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11; 66(7): 976–82PubMedCrossRefGoogle Scholar
  13. 13.
    Barichella M, Marczewska A, De Notaris R, et al. Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson’s disease. Mov Disord 2006 Oct; 21(10): 1682–7PubMedCrossRefGoogle Scholar
  14. 14.
    Barichella M, Savardi C, Mauri A, et al. Diet with LPP for renal patients increases daily energy expenditure and improves motor function in parkinsonian patients with motor fluctuations. Nutr Neurosci 2007 Jun–Aug; 10(3–4): 129–35PubMedCrossRefGoogle Scholar
  15. 15.
    de Lau LM, Bornebroek M, Witteman JC, et al. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 2005 Jun 28; 64(12): 2040–5PubMedCrossRefGoogle Scholar
  16. 16.
    Vanitallie TB, Nonas C, Di Rocco A, et al. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 2005 Feb 22; 64(4): 728–30PubMedCrossRefGoogle Scholar
  17. 17.
    Gao X, Chen H, Choi HK, et al. Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol 2008 Apr 1; 167(7): 831–8PubMedCrossRefGoogle Scholar
  18. 18.
    Chen H, O’Reilly E, McCullough ML, et al. Consumption of dairy products and risk of Parkinson’s disease. Am J Epidemiol 2007 May 1; 165(9): 998–1006PubMedCrossRefGoogle Scholar
  19. 19.
    Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 2007 Nov; 86(5): 1486–94PubMedGoogle Scholar
  20. 20.
    Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s disease. Curr Clin Pharmacol 2007 Sep; 2(3): 234–43PubMedCrossRefGoogle Scholar
  21. 21.
    Cooper MK, Brock DG, McDaniel CM. Interaction between levodopa and enteral nutrition. Ann Pharmacother 2008 Mar; 42(3): 439–42PubMedCrossRefGoogle Scholar
  22. 22.
    Gillespie NG, Mena I, Cotzias GC, et al. Diets affecting treatment of parkinsonism with levodopa. J Am Diet Assoc 1973 May; 62(5): 525–8PubMedGoogle Scholar
  23. 23.
    Mena I, Cotzias GC. Protein intake and treatment of Parkinson’s disease with levodopa. N Engl J Med 1975 Jan 23; 292(4): 181–4PubMedCrossRefGoogle Scholar
  24. 24.
    Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol 1987 Mar; 44(3): 270–2PubMedCrossRefGoogle Scholar
  25. 25.
    Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr 2008 Oct; 27(5): 675–84PubMedCrossRefGoogle Scholar
  26. 26.
    Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 2006 Sep; 17(5–6): 431–9PubMedCrossRefGoogle Scholar
  27. 27.
    Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 2002 Sep; 17(5): 867–76PubMedCrossRefGoogle Scholar
  28. 28.
    Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson’s disease. Mov Disord 2007 Jun 15; 22(8): 1133–7PubMedCrossRefGoogle Scholar
  29. 29.
    Schlesinger I, Schlesinger N. Uric acid in Parkinson’s disease. Mov Disord 2008 Sep 15; 23(12): 1653–7PubMedCrossRefGoogle Scholar
  30. 30.
    Newmark HL, Newmark J. Vitamin D and Parkinson’s disease: a hypothesis. Mov Disord 2007 Mar 15; 22(4): 461–8PubMedCrossRefGoogle Scholar
  31. 31.
    Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967 May; 17(5): 427–42PubMedCrossRefGoogle Scholar
  32. 32.
    Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008 Jun; 65(6): 716–23PubMedCrossRefGoogle Scholar
  33. 33.
    Sofi F, Cesari F, Abbate R, et al. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008; 337: a1344PubMedCrossRefGoogle Scholar
  34. 34.
    Bender A, Koch W, Elstner M, et al. Creatine supple-mentation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006 Oct 10; 67(7): 1262–4PubMedCrossRefGoogle Scholar
  35. 35.
    The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006 Mar 14; 66(5): 664–71CrossRefGoogle Scholar
  36. 36.
    The NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 2008 May–Jun; 31(3): 141–50CrossRefGoogle Scholar
  37. 37.
    Haas CT, Turbanski S, Kessler K, et al. The effects of random whole-body-vibration on motor symptoms in Parkinson’s disease. NeuroRehabilitation 2006; 21(1): 29–36PubMedGoogle Scholar
  38. 38.
    Di Rocco A, Rogers JD, Brown R, et al. S-Adenosylmethionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord 2000 Nov; 15(6): 1225–9PubMedCrossRefGoogle Scholar
  39. 39.
    Müller T, Fowler B, Kuhn W. Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson disease. Clin Neuropharmacol 2005 Nov–Dec; 28(6): 274–6PubMedCrossRefGoogle Scholar
  40. 40.
    Lamango NS, Nesby RA, Charlton CG. Quantification of S-adenosylmethionine-induced tremors: a possible tremor model for Parkinson’s disease. Pharmacol Biochem Behav 2000 Mar; 65(3): 523–9PubMedCrossRefGoogle Scholar
  41. 41.
    Campbell RR, Hasinoff B, Chernenko G, et al. The effect of ferrous sulfate and pH on L-dopa absorption. Can J Physiol Pharmacol 1990 May; 68(5): 603–7PubMedCrossRefGoogle Scholar
  42. 42.
    Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 2005 Jun; 4(6): 362–5PubMedCrossRefGoogle Scholar
  43. 43.
    Chen H, Zhang SM, Schwarzschild MA, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol 2004 Aug 15; 160(4): 368–75PubMedCrossRefGoogle Scholar
  44. 44.
    de Lau LM, Koudstaal PJ, Witteman JC, et al. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 2006 Jul 25; 67(2): 315–8PubMedCrossRefGoogle Scholar
  45. 45.
    The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007 Jan 2; 68(1): 20–8CrossRefGoogle Scholar
  46. 46.
    Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q (10) in Parkinson disease. Arch Neurol 2007 Jul; 64(7): 938–44PubMedCrossRefGoogle Scholar
  47. 47.
    Hague T, Andrews PL, Barker J, et al. Dietary chelators as antioxidant enzyme mimetics: implications for dietary intervention in neurodegenerative diseases. Behav Pharmacol 2006 Sep; 17(5–6): 425–30PubMedCrossRefGoogle Scholar
  48. 48.
    Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair 2007 Mar–Apr; 21(2): 107–15PubMedCrossRefGoogle Scholar
  49. 49.
    Mesa JL, Ruiz JR, González-Gross MM, et al. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med 2002; 32(14): 903–44PubMedCrossRefGoogle Scholar
  50. 50.
    Müller T, Woitalla D, Fowler B, et al. 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 2002 Feb; 109(2): 175–9PubMedCrossRefGoogle Scholar
  51. 51.
    Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008 Dec 15; 23(16): 2267–302PubMedCrossRefGoogle Scholar
  52. 52.
    Gao X, Curhan G, Forman JP, et al. Vitamin C intake and serum uric acid concentration in men. J Rheumatol 2008 Sep; 35(9): 1853–8PubMedGoogle Scholar
  53. 53.
    Anderson C, Checkoway H, Franklin GM, et al. Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov Disord 1999 Jan; 14(1): 21–7PubMedCrossRefGoogle Scholar
  54. 54.
    Evatt ML, Delong MR, Khazai N, et al. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008 Oct; 65(10): 1348–52PubMedCrossRefGoogle Scholar
  55. 55.
    Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 1997 Nov; 49(5): 1273–8PubMedCrossRefGoogle Scholar
  56. 56.
    Sato Y, Manabe S, Kuno H, et al. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999 Jan; 66(1): 64–8PubMedCrossRefGoogle Scholar
  57. 57.
    Sato Y, Honda Y, Iwamoto J, et al. Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord 2005 Dec; 20(12): 1598–603PubMedCrossRefGoogle Scholar
  58. 58.
    Obeid R, McCaddon A, Herrmann W. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases. Clin Chem Lab Med 2007; 45(12): 1590–606PubMedGoogle Scholar
  59. 59.
    Qureshi GA, Qureshi AA, Devrajani BR, et al. Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson’s patients? CNS Neurol Disord Drug Targets 2008 Feb; 7(1): 20–7PubMedCrossRefGoogle Scholar
  60. 60.
    Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J 2004 Jul; 148(1): 34–40PubMedCrossRefGoogle Scholar
  61. 61.
    Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinson’s disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005 May; 12(5): 365–8PubMedCrossRefGoogle Scholar
  62. 62.
    Postuma RB, Espay AJ, Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006 Jun 27; 66(12): 1941–3PubMedCrossRefGoogle Scholar
  63. 63.
    Zesiewicz TA, Wecker L, Sullivan KL, et al. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 2006 May–Jun; 29(3): 106–11PubMedCrossRefGoogle Scholar
  64. 64.
    Zoccolella S, Iliceto G, deMari M, et al. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review. Clin Chem Lab Med 2007; 45(12): 1607–13PubMedCrossRefGoogle Scholar
  65. 65.
    Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999 May 13; 340(19): 1449–54PubMedCrossRefGoogle Scholar
  66. 66.
    Klawans HL, Ringel SP, Shenker DM. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor. J Neurol Neurosurg Psychiatry 1971 Dec; 34(6): 682–6PubMedCrossRefGoogle Scholar
  67. 67.
    O’Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004 Jun; 61(6): 865–8PubMedCrossRefGoogle Scholar
  68. 68.
    Triantafyllou NI, Nikolaou C, Boufidou F, et al. Folate and vitamin B12 levels in levodopa-treated Parkinson’s disease patients: their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat Disord 2008; 14(4): 321–5PubMedCrossRefGoogle Scholar
  69. 69.
    Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002 Oct; 59(10): 1541–50PubMedCrossRefGoogle Scholar
  70. 70.
    Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson’s disease neuroprotection futility studies. Ann Neurol 2005 Feb; 57(2): 197–203PubMedCrossRefGoogle Scholar
  71. 71.
    MedlinePlus. Coenzyme Q10 [online]. Available from URL: http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-coenzymeq10.html [Accessed 2009 Jun 16]
  72. 72.
    Chung V, Liu L, Bian Z, et al. Efficacy and safety of herbal medicines for idiopathic Parkinson’s disease: a systematic review. Mov Disord 2006 Oct; 21(10): 1709–15PubMedCrossRefGoogle Scholar
  73. 73.
    Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004 Dec; 75(12): 1672–7PubMedCrossRefGoogle Scholar
  74. 74.
    Sharma H, Chandola HM, Singh G, et al. Utilization of Ayurveda in health care: an approach for prevention, health promotion, and treatment of disease: II. Ayurveda in primary health care. J Altern Complement Med 2007 Dec; 13(10): 1135–50CrossRefGoogle Scholar
  75. 75.
    Dhanasekaran M, Tharakan B, Manyam BV. Antiparkinson drug: Mucuna pruriens shows antioxidant and metal chelating activity. Phytother Res 2008 Jan; 22(1): 6–11PubMedCrossRefGoogle Scholar
  76. 76.
    Deleu D, Jacob P, Chand P, et al. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 2006 Sep 12; 67(5): 897–9PubMedCrossRefGoogle Scholar
  77. 77.
    Kitagawa M, Houzen H, Tashiro K. Effects of caffeine on the freezing of gait in Parkinson’s disease. Mov Disord 2007 Apr 15; 22(5): 710–2PubMedCrossRefGoogle Scholar
  78. 78.
    Quik M, O’Leary K, Tanner CM. Nicotine and Parkinson’s disease: implications for therapy. Mov Disord 2008 Sep 15; 23(12): 1641–52PubMedCrossRefGoogle Scholar
  79. 79.
    Villafane G, Cesaro P, Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson’s disease: an open trial. Eur J Neurol 2007 Dec; 14(12): 1313–6PubMedCrossRefGoogle Scholar
  80. 80.
    Simon DK, Swearingen CJ, Hauser RA, et al. Caffeine and progression of Parkinson disease. Clin Neuropharmacol 2008 Jul–Aug; 31(4): 189–96PubMedCrossRefGoogle Scholar
  81. 81.
    Kandinov B, Giladi N, Korczyn AD. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson’s disease. Parkinsonism Relat Disord 2007 May; 13(4): 243–5PubMedCrossRefGoogle Scholar
  82. 82.
    Goodwin VA, Richards SH, Taylor RS, et al. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2008 Apr 15; 23(5): 631–40PubMedCrossRefGoogle Scholar
  83. 83.
    Dibble LE, Hale TF, Marcus RL, et al. High-intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson’s disease. Mov Disord 2006 Sep; 21(9): 1444–52PubMedCrossRefGoogle Scholar
  84. 84.
    Falvo MJ, Schilling BK, Earhart GM. Parkinson’s disease and resistive exercise: rationale, review, and recommendations. Mov Disord 2008 Jan; 23(1): 1–11PubMedCrossRefGoogle Scholar
  85. 85.
    Fisher BE, Wu AD, Salem GJ, et al. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson’s disease. Arch Phys Med Rehabil 2008 Jul; 89(7): 1221–9PubMedCrossRefGoogle Scholar
  86. 86.
    Klein PJ, Rivers L. Taiji for individuals with Parkinson disease and their support partners: a program evaluation. J Neurol Phys Ther 2006 Mar; 30(1): 22–7PubMedGoogle Scholar
  87. 87.
    Schmitz-Hübsch T, Pyfer D, Kielwein K, et al. Qigong exercise for the symptoms of Parkinson’s disease: a randomized, controlled pilot study. Mov Disord 2006 Apr; 21(4): 543–8PubMedCrossRefGoogle Scholar
  88. 88.
    Burini D, Farabollini B, Iacucci S, et al. A randomised controlled cross-over trial of aerobic training versus Qigong in advanced Parkinson’s disease. Eura Medicophys 2006 Sep; 42(3): 231–8PubMedGoogle Scholar
  89. 89.
    Ashburn A, Fazakarley L, Ballinger C, et al. A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007 Jul; 78(7): 678–84PubMedCrossRefGoogle Scholar
  90. 90.
    Caglar AT, Gurses HN, Mutluay FK, et al. Effects of home exercises on motor performance in patients with Parkinson’s disease. Clin Rehabil 2005 Dec; 19(8): 870–7PubMedCrossRefGoogle Scholar
  91. 91.
    Lun V, Pullan N, Labelle N, et al. Comparison of the effects of a self-supervised home exercise program with a physiotherapist-supervised exercise program on the motor symptoms of Parkinson’s disease. Mov Disord 2005 Aug; 20(8): 971–5PubMedCrossRefGoogle Scholar
  92. 92.
    Farley BG, Koshland GF. Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson’s disease. Exp Brain Res 2005 Dec; 167(3): 462–7PubMedCrossRefGoogle Scholar
  93. 93.
    Protas EJ, Mitchell K, Williams A, et al. Gait and step training to reduce falls in Parkinson’s disease. Neuro-Rehabilitation 2005; 20(3): 183–90PubMedGoogle Scholar
  94. 94.
    Brichetto G, Pelosin E, Marchese R, et al. Evaluation of physical therapy in parkinsonian patients with freezing of gait: a pilot study. Clin Rehabil 2006 Jan; 20(1): 31–5PubMedCrossRefGoogle Scholar
  95. 95.
    Ellis T, de Goede CJ, Feldman RG, et al. Efficacy of a physical therapy program in patients with Parkinson’s disease: a randomized controlled trial. Arch Phys Med Rehabil 2005 Apr; 86(4): 626–32PubMedCrossRefGoogle Scholar
  96. 96.
    del Olmo MF, Cudeiro J. Temporal variability of gait in Parkinson disease: effects of a rehabilitation programme based on rhythmic sound cues. Parkinsonism Relat Disord 2005 Jan; 11(1): 25–33PubMedCrossRefGoogle Scholar
  97. 97.
    del Olmo MF, Arias P, Furio MC, et al. Evaluation of the effect of training using auditory stimulation on rhythmic movement in parkinsonian patients: a combined motor and [18F]-FDG PET study. Parkinsonism Relat Disord 2006 Apr; 12(3): 155–64PubMedCrossRefGoogle Scholar
  98. 98.
    Hausdorff JM, Lowenthal J, Herman T, et al. Rhythmic auditory stimulation modulates gait variability in Parkinson’s disease. Eur J Neurosci 2007 Oct; 26(8): 2369–75PubMedCrossRefGoogle Scholar
  99. 99.
    Rochester L, Nieuwboer A, Baker K, et al. The attentional cost of external rhythmical cues and their impact on gait in Parkinson’s disease: effect of cue modality and task complexity. J Neural Transm 2007; 114(10): 1243–8PubMedCrossRefGoogle Scholar
  100. 100.
    van Wegen E, Lim I, de Goede C, et al. The effects of visual rhythms and optic flow on stride patterns of patients with Parkinson’s disease. Parkinsonism Relat Disord 2006 Jan; 12(1): 21–7PubMedCrossRefGoogle Scholar
  101. 101.
    Tamir R, Dickstein R, Huberman M. Integration of motor imagery and physical practice in group treatment applied to subjects with Parkinson’s disease. Neurorehabil Neural Repair 2007 Jan–Feb; 21(1): 68–75PubMedCrossRefGoogle Scholar
  102. 102.
    Turbanski S, Haas CT, Schmidtbleicher D, et al. Effects of random whole-body vibration on postural control in Parkinson’s disease. Res Sports Med 2005 Jul–Sep; 13(3): 243–56PubMedCrossRefGoogle Scholar
  103. 103.
    Ebersbach G, Edler D, Kaufhold O, et al. Whole body vibration versus conventional physiotherapy to improve balance and gait in Parkinson’s disease. Arch Phys Med Rehabil 2008 Mar; 89(3): 399–403PubMedCrossRefGoogle Scholar
  104. 104.
    Comella CL, Stebbins GT, Brown-Toms N, et al. Physical therapy and Parkinson’s disease: a controlled clinical trial. Neurology 1994 Mar; 44 (3 Pt 1): 376–8PubMedCrossRefGoogle Scholar
  105. 105.
    Watts JJ, McGinley J, Huxham F, et al. Cost effectiveness of preventing falls and improving mobility in people with Parkinson disease: protocol for an economic evaluation alongside a clinical trial. BMC Geriatr 2008 Sep 30; 8(1): 23–30PubMedCrossRefGoogle Scholar
  106. 106.
    Paterson C, Allen JA, Browning M, et al. A pilot study of therapeutic massage for people with Parkinson’s disease: the added value of user involvement. Complement Ther Clin Pract 2005 Aug; 11(3): 161–71PubMedCrossRefGoogle Scholar
  107. 107.
    Svircev A, Craig LH, Juncos JL. A pilot study examining the effects of neuromuscular therapy on patients with Parkinson’s disease [abstract]. J Am Osteopath Assoc 2005 Jan; 105(1): 26PubMedGoogle Scholar
  108. 108.
    Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease: a randomized, double blind, placebo-controlled study. J Neurol 2007 Apr; 254(4): 459–64PubMedCrossRefGoogle Scholar
  109. 109.
    Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 2005 Sep; 6(5): 459–66PubMedCrossRefGoogle Scholar
  110. 110.
    Paus S, Schmitz-Hübsch T, Wüllner U, et al. Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord 2007 Jul 30; 22(10): 1495–8PubMedCrossRefGoogle Scholar
  111. 111.
    Willis GL, Turner EJ. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol Int 2007; 24(3): 521–37PubMedCrossRefGoogle Scholar
  112. 112.
    Eng ML, Lyons KE, Greene MS, et al. Open-label trial regarding the use of acupuncture and yin tui na in Parkinson’s disease outpatients: a pilot study on efficacy, tolerability, and quality of life. J Altern Complement Med 2006 May; 12(4): 395–9PubMedCrossRefGoogle Scholar
  113. 113.
    Cristian A, Katz M, Cutrone E, et al. Evaluation of acupuncture in the treatment of Parkinson’s disease: a double-blind pilot study. Mov Disord 2005 Sep; 20(9): 1185–8PubMedCrossRefGoogle Scholar
  114. 114.
    Trinh K, Graham N, Gross A, et al. Acupuncture for neck disorders. Spine 2007 Jan 15; 32(2): 236–43PubMedCrossRefGoogle Scholar
  115. 115.
    Inzelberg R, Peleg N, Nisipeanu P, et al. Inspiratory muscle training and the perception of dyspnea in Parkinson’s disease. Can J Neurol Sci 2005 May; 32(2): 213–7PubMedGoogle Scholar
  116. 116.
    Silverman EP, Sapienza CM, Saleem A, et al. Tutorial on maximum inspiratory and expiratory mouth pressures in individuals with idiopathic Parkinson disease (IPD) and the preliminary results of an expiratory muscle strength training program. NeuroRehabilitation 2006; 21(1): 71–9PubMedGoogle Scholar
  117. 117.
    Deane KH, Whurr R, Playford ED, et al. Speech and language therapy for dysarthria in Parkinson’s disease. Cochrane Database Syst Rev 2001; (2): CD002812Google Scholar
  118. 118.
    Deane KH, Whurr R, Playford ED, et al. A comparison of speech and language therapy techniques for dysarthria in Parkinson’s disease. Cochrane Database Syst Rev 2001; (2): CD002814Google Scholar
  119. 119.
    Sapir S, Spielman JL, Ramig LO, et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J Speech Lang Hear Res 2007 Aug; 50(4): 899–912PubMedCrossRefGoogle Scholar
  120. 120.
    Sturtzel B, Elmadfa I. Intervention with dietary fiber to treat constipation and reduce laxative use in residents of nursing homes. Ann Nutr Metab 2008; 52 Suppl. 1: 54–6CrossRefGoogle Scholar
  121. 121.
    Astarloa R, Mena MA, Sánchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992 Oct; 15(5): 375–80PubMedCrossRefGoogle Scholar
  122. 122.
    El Sharkawi A, Ramig L, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry 2002 Jan; 72(1): 31–6PubMedCrossRefGoogle Scholar
  123. 123.
    Sunagane N, Aikawa M, Ohta T, et al. Possibility of interactions between prescription drugs and OTC drugs (2nd report): interaction between levodopa preparation and OTC Kampo medicines for upset stomach. Yakugaku Zasshi 2006 Nov; 126(11): 1191–6PubMedCrossRefGoogle Scholar
  124. 124.
    Rodrigues de Paula F, Teixeira-Salmela LF, Coelho de Morais Faria CD, et al. Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Mov Disord 2006 Aug; 21(8): 1073–7PubMedCrossRefGoogle Scholar
  125. 125.
    Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65(9): 1239–82PubMedCrossRefGoogle Scholar
  126. 126.
    Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006 Sep; 13(9): 930–6PubMedCrossRefGoogle Scholar
  127. 127.
    Schoffer KL, Henderson RD, O’Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord 2007 Aug 15; 22(11): 1543–9PubMedCrossRefGoogle Scholar
  128. 128.
    Deane KH, Ellis-Hill C, Jones D, et al. Systematic review of paramedical therapies for Parkinson’s disease. Mov Disord 2002 Sep; 17(5): 984–91PubMedCrossRefGoogle Scholar
  129. 129.
    Verbaan D, Marinus J, Visser M, et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007 Jul 24; 69(4): 333–41PubMedCrossRefGoogle Scholar
  130. 130.
    Visser M, Marinus J, van Hilten JJ, et al. Assessing comorbidity in patients with Parkinson’s disease. Mov Disord 2004 Jul; 19(7): 824–8PubMedCrossRefGoogle Scholar
  131. 131.
    Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 2007 Sep; 13 Suppl.: S2–7PubMedCrossRefGoogle Scholar
  132. 132.
    Lorefät B, Ganowiak W, Wissing U, et al. Food habits and intake of nutrients in elderly patients with Parkinson’s disease. Gerontology 2006; 52(3): 160–8PubMedCrossRefGoogle Scholar
  133. 133.
    Chen H, Zhang SM, Hernán MA, et al. Weight loss in Parkinson’s disease. Ann Neurol 2003 May; 53(5): 676–9PubMedCrossRefGoogle Scholar
  134. 134.
    Deane KH, Whurr R, Clarke CE, et al. Non-pharmacological therapies for dysphagia in Parkinson’s disease. Cochrane Database Syst Rev 2001; (1): CD002816Google Scholar
  135. 135.
    Senard JM, Brefel-Courbon C, Rascol O, et al. Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management. Drugs Aging 2001; 18(7): 495–505PubMedCrossRefGoogle Scholar
  136. 136.
    Martínez-Martín P, Tolosa E, Hernández B, et al. The patient card questionnaire to identify wearing-off in Parkinson disease. Clin Neuropharmacol 2007 Sep–Oct; 30(5): 266–75PubMedCrossRefGoogle Scholar
  137. 137.
    Santens P, de Noordhout AM, for the Belgian EODWO Study Group. Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson’s disease using a dedicated questionnaire: a Belgian multicenter survey. Acta Neurol Belg 2006 Sep; 106(3): 137–41PubMedGoogle Scholar
  138. 138.
    Stacy MA, Murphy JM, Greeley DR, et al. The sensitivity and specificity of the 9-item wearing-off questionnaire. Parkinsonism Relat Disord 2008; 14(3): 205–12PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Parkinson Research Foundation, Department of NeurologyUniversity of South FloridaTampaUSA
  2. 2.Department of NeurologyEmory University School of MedicineAtlantaUSA

Personalised recommendations